SLC5A2 and Hypoglycemia: This is consistent with our previous results [20], and with the use of SGLT-2 inhibitors in humans, where the risk of hypoglycaemia is considered low, as the renal threshold for glucose excretion is not lowered to the point of the hypoglycemic threshold [26].